Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Licenses Allelica Polygenic Risk Score Software

NEW YORK – Allelica said on Thursday that Illumina is licensing its software for developing polygenic risk scores (PRS).

The agreement allows Illumina to offer Allelica's PRS technology to its customers via its Illumina Connected Analytics bioinformatics software platform, enabling them to identify individuals with a high genetic risk of developing life-threatening diseases.

Allelica said its platform streamlines the polygenic risk scoring process, from imputation and development to validation across multiple ancestries and for a range of disorders.

"Integrating the first PRS module into the Illumina Connected Analytics platform will help empower researchers to mature the field of polygenic risk score utility and help transform the way we think about human health," Ashley Van Zeeland, head of Illumina Open Innovation, said in a statement.

The collaboration also includes codevelopment of an Illumina Infinium genotyping array that includes curated content specific for PRS predictions.

Allelica also recently partnered with a Yale University researcher to develop PRS related to neuropsychiatric disorders.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.